Q4FY17 Results: Neuland Laboratories Ltd

Neuland Laboratories Ltd. reported its results for the quarter ended March 31, 2017. 

The company's total sales for Q3FY17 came in at Rs 140.95 crore, which represents a 6.43 per cent sequential increase and 4.41 per cent YoY increase.

Its operating profit (EBIT) for the quarter amounted to Rs 17.49 crore and its EBIT margin stood at 12.41 per cent.

The company reported PAT of Rs 8.5 crore, which represents a sequential QoQ increase of 123.68 per cent and a YoY increase of 28.79 per cent.

The company's stock at Rs. 1360.4 on the BSE, rose 1.82 per cent to Rs 1370.95. It hit intra-day high and low of Rs 1394.8 and Rs 1343.65, respectively.

Neuland Laboratories Ltd is an India-based pharmaceutical company. The company is engaged on manufacture of APIs, contract research and contract manufacturing. The products of company are Albuterol/Salbutanol sulphate, Aripiprazole, Ciprofloxacin Hydrochoride, Darifenacin Hydriobfomide, Enalapril Maleate etc.